Preemptive analgesia of nepafenac 0.1% in retinal photocoagulation

Objective:

To evaluate the preemptive effect of nepafenac 0,1% in patients undergoing retinal photocoagulation for the treatment of proliferative diabetic retinopathy

Methods:

Thirty patients underwent argon laser photocoagulation in both eyes. The contralateral eye of each patient was the control. The nepafenac and placebo were used 30 minutes before the application of the laser. Both eyes were photocoagulated in the same day. Pain intensity was assessed by visual analog scale and descriptive pain scale

Results:

The analysis of the interaction instillation versus nepafenac showed that patients in the placebo group had similar levels of pain in both eyes, and the nepafenac group had significant reduction in pain in the eye that was instilled suspension of 0,1% when compared to the contralateral eye which received placebo (p = 0.023).

Conclusion:

This study suggests that a suspension of 0,1% nepafenac helpful for preemptive analgesia in patients undergoing retinal photocoagulation compared to placebo.

Pain/prevent & control; Analgesia; Anti-inflammatory agents, non-steroidal/administration & dosage; Anti-inflammatory agents, non-steroidal/therapeutic use; Light coagulation; Diabetic retinopathy/drug therapy